Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus IgG Tests to Identify Persons Eligible for Dengue Vaccination
Medina, Freddy A. ¹ , Vila, Frances ¹ , Adams, Laura E. ¹ , Cardona, Jaime ¹ , Carrion, Jessica ¹ ,
Lamirande, Elaine ³ , Acosta, Luz, N. ¹ , De León-Rodríguez, Carlos M. ¹ , Beltran, Manuela ¹ , Grau,
Demian ¹ , Rivera-Amill, Vanessa ² , Balmaseda, Angel ^{4,5} , Harris, Eva ⁶ , Madewell, Zachary J. ¹ ,
Waterman, Stephen H. ¹ , Paz-Bailey, Gabriela ¹ , Whitehead, Stephen ³ , Muñoz-Jordán, Jorge L. ^{1*}
1. Centers for Disease Control and Prevention (CDC), San Juan, PR, USA
2. Ponce Health Sciences University/Ponce Research Institute, Ponce, PR, USA
3. National Institutes of Health (NIH), Bethesda, MD, USA
4. Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia,
Ministerio de Salud, Managua, Nicaragua
5. Sustainable Sciences Institute, Managua, Nicaragua
6. Division of Infectious Diseases and Vaccinology, School of Public Health, University of
California, Berkeley, Berkeley, California USA
Keywords: Zika, dengue, virus, pre-vaccination, vaccine, screening, cross-reactivity, IgG,
ELISA, rapid diagnostic test
Running title: Evaluation of dengue virus IgG Tests for pre-vaccination screening

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

23 Abstract Word Count: 239

- **Text Word Count:** 2,631 words, exclusive of the abstract, Materials and Methods, references,
- tables, and figure legends

Figures: 2

- **Tables: 5**
- 28 Supplemental tables: 1

29 Supplemental figures: 12

- ...

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

42 Abstract

43 The Advisory Committee on Immunization Practices (ACIP) recommended that dengue pre-44 vaccination screening tests for Dengvaxia administration have at least 98% specificity and 75% sensitivity. This study evaluates the performance of commercial anti-DENV IgG tests to identify 45 tests that could be used for pre-vaccination screening. First, for 7 tests, we evaluated sensitivity 46 47 and specificity in early convalescent dengue virus (DENV) infection, using 44 samples collected 7-30 days after symptom onset and confirmed by RT-PCR. Next, for the 5 best performing tests 48 49 and two additional tests (with and without an external test reader) that became available later, we evaluated performance to detect past dengue infection among a panel of 44 specimens collected 50 in 2018-2019 from healthy 9-16-year-old children from Puerto Rico. Finally, a full-scale 51 evaluation was done with the 4 best performing tests using 400 specimens from the same 52 population. We used virus focus reduction neutralization test and an in-house DENV IgG ELISA 53 54 as reference standards.

Of seven tests, five showed ≥75% sensitivity detecting anti-DENV IgG in early convalescent specimens with low cross-reactivity to Zika virus. For the detection of previous DENV infections the tests with the highest performance were the Euroimmun NS1 IgG ELISA (sensitivity 84.5%, specificity 97.1%) and CTK Dengue IgG rapid test R0065C with the test reader (sensitivity 76.2% specificity 98.1%). There are IgG tests available that can be used to accurately classify individuals with previous DENV infection as eligible for dengue vaccination to support safe vaccine implementation.

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

63 Introduction

64	The mosquito-borne dengue virus (DENV) is a growing threat globally. Approximately half of
65	the world's population lives in at-risk areas, and there are almost 400 million infections annually
66	(1, 2). There are four related, but antigenically distinct DENV serotypes that can produce
67	symptomatic disease in approximately 25% of infections. Individuals with dengue can
68	experience a range of symptoms, from mild manifestations to severe disease that requires
69	hospitalization and can result in death. Infection with one DENV serotype is thought to provide
70	lifelong immunity against the infecting serotype. After a primary DENV infection, the antibody
71	levels wane after 6-9 months to a level where they remain stable for years, and the risk of
72	developing severe illness during a second infection with any of the other three serotypes
73	increases (3). The risk of severe dengue decreases for the third and fourth DENV infections.
74	Implementing Dengvaxia [®] , the first licensed dengue vaccine is complicated by the necessity of
75	confirming a previous dengue infection prior to vaccination. In 2019, the Food and Drug
76	Administration (FDA) approved Dengvaxia [®] for individuals aged 9-16 years who have a
77	laboratory-confirmed previous DENV infection and live in endemic areas of the United States.
78	After careful review, the Centers for Disease Control and Prevention (CDC) Advisory
79	Committee on Immunization Practices (ACIP) recommended the use of Dengvaxia® in 2021, and
80	provided guidance for its implementation in the United States and its territories and freely
81	associated states (4). Tests to be used for determining previous dengue infections prior to
82	vaccination must have a minimum of \geq 75% sensitivity and \geq 98% specificity, with a
83	neutralizing antibody titer at 50% inhibition (NT50) as the reference standard for the United
84	States (4, 5). These criteria were based on evidence that although a previous DENV infection can
85	be demonstrated by laboratory-confirmed RT-PCR detection or a positive NS1 test during the

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

86 acute phase of infection, a large proportion of DENV infections are asymptomatic or mildly symptomatic and may not have been tested or records of previous testing may not have been 87 maintained. Evidence of a previous DENV infection by serological testing for anti-DENV IgG 88 antibodies is the most feasible recommendation but can be problematic due to the cross-89 reactivity between DENV and other flaviviruses such as Zika virus (ZIKV), which circulated in 90 91 many dengue-endemic areas. Although there are many commercial tests for the detection of anti-DENV IgG, none of them are currently licensed by the FDA, and most were developed for 92 diagnostic purposes during the early convalescent phase of infection, when antibody levels are 93 94 high, rather than for determining serostatus years after infection when antibody levels are lower. Moreover, many of the currently available commercial anti-DENV IgG tests were developed 95 prior to the emergence of ZIKV and little is known about the level of flavivirus cross-reactivity 96 that occurs in these tests. A systematic review in 2019 did not identify studies describing the 97 evaluation of lateral flow tests for the detection of anti-DENV IgG long after (≥ 1 year) infection 98 that could indicate a potential use of these tests for pre-vaccination screening (6). Since then, 99 limited publications describe evaluations of tests for the purpose of pre-vaccination screening; 100 but studies using side-by-side comparisons of commercial tests with specimens from typical 101 102 eligible healthy candidates are lacking (7-11). Comparative studies are needed to determine the best commercial anti-DENV IgG tests to guide dengue vaccine implementation efforts in the 103 United States. 104

Our aim in this study was to determine the sensitivity and specificity of commercial anti-DENV
IgG tests that could be used to accurately classify individuals with previous DENV infection
(PDI) as eligible for dengue vaccination in the United States as recommended by the ACIP.
Serum specimens used for comparisons were obtained from Puerto Rico, the jurisdiction with the

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

109	largest population at risk for dengue transmission in the United States. The specimens were from
110	two sources: early convalescent, well-characterized specimens from people with DENV or ZIKV
111	confirmed by RT-PCR or negative for both viruses, and samples from healthy 9–16-year-old
112	children whose immune status was characterized by the combined results of a DENV/ZIKV
113	focus reduction neutralization test (FRNT) and the CDC DENV IgG ELISA.
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

128 Methods

129

130 Participant enrollment and ethics statement

131	Early convalescen	t specimens we	ere retrospectively	^v obtained	from the	Sentinel	Enhanced I	Dengue
-----	-------------------	----------------	---------------------	-----------------------	----------	----------	------------	--------

and Acute Febrile Illness Surveillance System (SEDSS), as described previously (12, 13).

133 Samples to evaluate test performance for previous dengue infections were retrospectively

134 obtained from the Communities Organized to Prevent Arboviruses (COPA) project in Puerto

135 Rico that conducts annual serosurveys among participants 1-50 years of age. Participants were

136 recruited into COPA as previously described with written informed consent or assent obtained

137 from all study participants according to a protocol approved by Institutional Review Boards at

the Centers for Disease Control and Prevention (CDC) and Ponce Medical School Foundation,

139 Inc (PMSF). We used random samples among non-ill children 9-16 years of age collected in

140 2018 and 2019 (14). Specimens from primary ZIKV infections were obtained from a pediatric

141 cohort in Nicaragua collected in 2018 and 2019 (15). The ZIKV infections were confirmed by

real-time RT-PCR during the acute episodes in 2016, and absence of DENV infections was

143 confirmed in paired annual samples tested with a DENV inhibition ELISA (16).

144

145 **Test selection**

A search was performed for commercial tests that detect anti-DENV IgG. A total of 60 tests (46
ELISA and 14 rapid diagnostic tests [RDT]) from 34 manufacturers were identified. This group
was narrowed down to 23 tests (11 ELISAs, 12 RDTs) by selecting only tests that reported
performance data on their website or in their instructions for use. All but two tests reported

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

150	greater than 90% specificity. The tests with sensitivity lower than 75% were removed from
151	consideration. This group was further reduced to 7 tests (5 ELISAs, 2 RDTs) since some
152	manufacturers or representatives were not reached after multiple attempts to contact them by
153	both e-mail and telephone (n=9), or if the manufacturer stated that the product was withdrawn
154	from sale (n=5). The 7 tests selected were included in the first phase of the evaluation to
155	determine performance in early convalescent specimens, as these tests have been manufactured
156	for use in disease diagnosis. Based on their performance, 5 of these tests were selected for further
157	analysis. During this evaluation, two versions of a rapid test manufactured by CTK Biotech
158	became available for the detection of IgG antibodies as an indication of prior DENV infection in
159	asymptomatic individuals. CTK Biotech also offers the Alta rapid test reader (RTR-1) as an
160	optional tool to automate and standardize the presence or absence of test line bands. Therefore, 7
161	tests moved to another round of the evaluation using a panel of samples from patients with
162	confirmed previous dengue infection: the 5 tests with highest accuracy selected from the
163	evaluation with early convalescent specimens and the 2 CTK test modalities. The 4 best
164	performing tests were further evaluated for detection of previous dengue infection in a survey of
165	healthy individuals. The tests used in these evaluations were purchased directly from the
166	manufacturers, stored at the recommended temperatures, and used prior to their expiration dates.
167	The 9 tests evaluated are listed in Table 1.

168

169 Focus reduction neutralization test (FRNT)

170 FRNT assays for DENV-1-4 were performed blinded at the Laboratory of Viral Diseases,

- 171 National Institute for Allergy, and Infectious Disease (NIAID), National Institutes of Health
- 172 (NIH) as previously described (17). Viruses used in the assay included: DENV-1 Western Pacific

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

173	(Nauru/74), DENV-2 NGC Prototype (1944), DENV-3 Sleman/78, and DENV-4 814669
174	(Dominica/81). Serum specimens were used at dilutions of 1:5, 1:20, and 1:80 with antibody
175	titers defined as the highest serum dilution that resulted in >50% reduction (FRNT50) in the
176	number of immunostained virus foci. A specimen was considered positive for neutralization
177	against the infecting serotype when the FRNT titer was >4 for DENV-1, >15 for DENV-2, >15
178	for DENV-3, and >4 for DENV-4 (Supplemental Figure S1). Specimens with no neutralizing
179	antibodies against a virus were given a value of 4. We used the FRNT50, considered the gold
180	standard for measuring neutralizing antibodies against dengue virus and other flaviviruses, in
181	combination with the CDC DENV IgG test as our reference standard.

182

183 CDC DENV IgG ELISA

The CDC DENV IgG assay was calibrated based on the NIH FRNT50 assay and a modified 184 version of Miagostovich et. al (18). Capture antibody (4G2 Mouse anti-Flavivirus Envelope 185 186 Protein, Native Antigen Company, Oxford, United Kingdom) was diluted 1:6,000 in 0.1 M carbonate-bicarbonate buffer pH 9.6 and plates were incubated overnight at 4°C. Plates were 187 washed three times in phosphate buffered saline (PBS) and incubated with blocking buffer (PBS 188 pH 7.4/0.05% Tween 20/3% normal goat serum) for 1 hour at 37°C. After removing blocking 189 buffer, a DENV-1-4 antigen mix (DENV-1-4 virus-like particle [VLP] recombinant antigens) 190 191 titrated between 0.1 ng/µl-0.7 ng/µl for each antigen, Native Antigen Company, Oxford, United Kingdom) diluted in blocking buffer was added to each well and incubated covered for 1 hour at 192 37°C. Plates were washed three times in PBS. Each plate contained a high positive control, low 193 194 positive control, high negative control, two low negative controls, and a cutoff control. Serum specimens, positive controls, negative controls, and a cutoff control were diluted 1:100 in a 195

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

- solution of PBS pH 7.4 containing 3% non-fat dry milk/ 0.05% Tween-20 and tested in
- 197 duplicate. The positive and cutoff controls were created using pooled early convalescent
- specimens collected 7–30 days post-onset (DPO) of symptoms from RT-PCR confirmed DENV-
- 199 1–4 cases and diluted in PBS. Plates were washed three times in PBS and a horse radish
- 200 peroxidase conjugated anti-human IgG diluted in a solution of PBS pH 7.4 containing 3% non-
- fat dry milk/ 0.05% Tween-20 was added and incubated in the dark for 1 hour uncovered at room
- temperature. Plates were washed six times with PBS and ABTS substrate added to each well.
- After a 60-minute room temperature incubation in the dark, plates were read in a microplate
- spectrophotometer at 405 nm without a blank. Optical density (OD) values and antibody index
- ratio (AIR) calculations for the controls and samples are needed for test run validation and
- 206 interpretation of results, accordingly.
- AIR = ([control or sample OD / cutoff control OD] *10)
- 208 Positive: AIR ≥ 15
- 209 Equivocal: AIR 10-14.99
- 210 Negative: AIR <10
- 211 Non-concordant results were repeated twice by CDC DENV IgG ELISA and FRNT50 to
- confirm results. All specimens except one were concordant in both assays.

213

214 ZIKV EDIII IgG ELISA

- 215 The ZIKV EDIII IgG ELISA was performed as previously described in Adams et. al. with the
- 216 modification of using diluted human monoclonal antibody ZKA190 as a cutoff control for inter-

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

217	plate consistency (19). High-binding microtiter 96-well plates (Greiner Bio-One) were coated
218	with streptavidin diluted to 4 μ g/mL in Tris-buffered saline (TBS, pH 7.4), and incubated for 1
219	hour at 37°C to ensure optimal binding. After incubation, the plate was decanted, washed thrice
220	with wash buffer (TBS containing 0.2% Tween 20). To minimize non-specific binding, the plate
221	was blocked using a blocking solution (3% milk in TBS containing 0.05% Tween 20) for 1 hour
222	at 37°C. Biotinylated EDIII antigen diluted at a concentration of 2 μ g/mL in blocking buffer was
223	captured in plates after a 1-hour incubation at 37°C. Plates were washed thrice with wash buffer.
224	After removal of the blocking solution, serum samples at a 1:20 dilution in blocking buffer were
225	added to each well and incubated for 1 hour at 37°C for binding of ZIKV-specific IgG antibodies
226	to the captured EDIII antigen. Following another series of three washes, goat anti-human IgG
227	alkaline phosphatase-conjugated secondary antibody (Sigma) was added at a 1:2,500 dilution and
228	incubated for 1 hour at 37°C. After a final washing, SigmaFast AP substrate was added, and the
229	reaction was developed in the dark for 30 minutes at room temperature. The plate was then read
230	at a 405 nm wavelength setting without a blank. For validation and interpretation of results,
231	optical density (OD) values and antibody index ratio (AIR) calculations were necessary for
232	controls and samples.

- AIR = ([control or sample OD / cutoff control OD] *10)
- 234 Positive: AIR > 10
- 235 Negative: AIR ≤ 10

236

237

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

239 Laboratory testing

240 *Early convalescent specimens*

241	A serum panel was assembled with early convalescent specimens (EC panel, N=44) collected 7-
242	30 (average = 12) days post-onset (DPO) of symptoms from cases in a convenience series within
243	SEDSS. These cases were confirmed as either DENV or ZIKV positive or negative by RT-PCR
244	on the first specimen collected from each case (DPO 0-5) and whose immune status was
245	determined based on testing a convalescent sample with the CDC DENV IgG or ZIKV IgG
246	assays, as previously described (19). Unexposed specimens (n=8) were negative in the CDC
247	Trioplex RT-PCR, negative for DENV and ZIKV IgG, and IgM negative in the acute and early
248	convalescent specimens for DENV and ZIKV. Specimens from ZIKV RT-PCR positive cases
249	with negative and DENV IgG negative results were named primary ZIKV (n=14). DENV
250	primary specimens (n=12) were DENV RT-PCR-positive and DENV and ZIKV IgG-negative.
251	DENV secondary specimens (n=8) were DENV RT-PCR positive, negative for ZIKV IgG, and
252	positive for DENV IgG.

253

254 *Previous DENV infection specimens*

255 The following immune status classification criteria were established for samples from a

serosurvey of asymptomatic 9-16 Y/O children (COPA) that were available for this study:

257 Specimens were classified as positive for DENV only if they were positive in the DENV FRNT

and CDC DENV IgG ELISA. Specimens that neutralized a single DENV serotype and were not

259 positive in the ZIKV EDIII IgG ELISA were classified as monotypic DENV, and specimens that

260 neutralized two or more DENV serotypes and were not positive by ZIKV EDIII IgG ELISA

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

261	were classified as multitypic DENV. Specimens that did not neutralize any DENV serotype and
262	were ZIKV EDIII IgG ELISA positive were classified as primary ZIKV. Specimens that
263	neutralized any DENV serotype and were positive in the ZIKV EDIII IgG ELISA were classified
264	as multi-flavivirus. Specimens that did not neutralize DENV nor tested ZIKV EDIII IgG ELISA
265	positive, and specimens that were only positive in the CDC DENV IgG ELISA or FRNT50 were
266	classified as unexposed.
267	We constructed a panel with 44 specimens selected out of from the total COPA serosurvey to
268	assess previous DENV infections (PDI). The 44 samples were classified according to the above-
269	stated immune status classification criteria for asymptomatic cases with the following
270	proportions: unexposed (n=8), primary ZIKV (n=14), monotypic DENV (n=13) and multitypic
271	DENV (n=9). Multi-flavivirus samples were not included in this panel. We then expanded our
272	evaluation to a panel of 400 samples from the COPA serosurvey, which included a blinded
273	selection of 50 specimens from each year of age (9–16), within a total of 750 participants of that
274	age group. These specimens were classified according to the same immune status clarification
275	criteria (Table 2). FRNT50 titers for the 400 samples for each DENV serotype according to their
276	immune status classification can be found in supplementary Figure S1.

277

278 Additional evaluation for cross-reactivity with ZIKV specimens

To ensure that the tests with high performance for pre-vaccination screening with Puerto Rico specimens had little cross-reactivity with ZIKV, we tested an additional 22 well-characterized RT-PCR-confirmed past ZIKV infections from a cohort in Nicaragua and an additional 41 specimens from unexposed healthy individuals from Puerto Rico, both obtained from cases of a

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

283	convenience series. In addition, 12 challenging samples from primary ZIKV positive patients
284	were selected for their high ZIKV neutralizing and binding antibody levels. The specimens were
285	collected at 3-4 months after RT-PCR confirmed infections in 2016-2017.

All serum specimens used in these evaluations were stored frozen after arrival to the CDC

287 Dengue Branch, thawed and prepared in aliquots for virus neutralization, CDC DENV IgG

288 ELISA, or commercial assay testing.

289 Specimen testing

290 Specimen testing was conducted contemporaneously with the index tests and reference standards 291 to ensure consistency and reliability in the results. All tests were performed and interpreted 292 according to the manufacturer's instructions for use and all specimens were tested in index tests 293 and the reference standard. There was no missing data. ELISA equivocal/borderline/weakly reactive results were considered negative for calculations of test performance. Testing was 294 performed by the same laboratory technician for all ELISA assays. Rapid tests were 295 independently interpreted visually by two laboratory technicians who were blinded to specimen 296 classifications. The CTK OnSite Dengue IgG Rapid Tests were also read with the CTK Alta 297 298 Rapid Test Reader RTR-1 optimized for visual readout with the large panel (PDI, n=400) collected from healthy children 9-16 years of age in Puerto Rico. There were no adverse events 299 associated with performing the index tests or the reference standard. This study was carried out 300 301 and documented following the Standards for Reporting Diagnostic Accuracy Studies (STARD) guidelines (20). Participant flow and outcomes for the index tests are depicted using STARD 302 303 flow diagrams (Figures S2-12). This study was conducted and reported in accordance with the 304 Standards for Reporting Diagnostic Accuracy Studies (STARD) guidelines. The flow of 305 participants for the index tests and their results was presented using STARD diagrams.

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

306 Sample Size Calculation

- 307 The sample size for our diagnostic accuracy of previous DENV infection specimens was
- 308 calculated based on the expected prevalence (45%) of Dengue in Puerto Rico and for the
- diagnostic tests expected to achieve a sensitivity of at least 75% and a specificity of 98% with a
- margin of error of $\pm 3\%$. The significance level (α) was set at 0.05. Using the previously
- described parameters for calculations, the minimum sample size required was 374.

312

313 Data analysis

- 314 Sensitivity
- 315 Test sensitivity was measured as the evaluated test's ability to correctly identify specimens that
- are positive for DENV IgG antibodies through two refence standards: the CDC DENV IgG
- 317 ELISA and the DENV FRNT50 assays. A specimen was confirmed as DENV IgG positive if it
- tested positive in both assays serving as reference standards. Sensitivity was calculated as the
- number of anti-DENV positive specimens correctly detected by the test under evaluation,
- 320 divided by the total number of anti-DENV positive specimens confirmed by CDC DENV IgG
- 321 ELISA and classified as DENV immune by FRNT50, multiplied by 100.

322

323 Specificity

324 Test specificity was measured as the evaluated test's ability to correctly identify specimens that

- 325 were not exposed to DENV (negative for DENV IgG antibodies) or were exposed to ZIKV only
- 326 (positive for ZIKV IgG antibodies but negative for DENV IgG antibodies). For this evaluation,

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

327	we considered non-concordant specimens—those that test positive in either the CDC DENV IgG
328	ELISA or the DENV FRNT50 assay but not in both—as negative for DENV IgG antibodies.
329	Specificity was calculated by adding the number of specimens that the evaluated tests correctly
330	identified as negative (including true negative, equivocal/borderline/weakly reactive and non-
331	concordant specimens) and only ZIKV exposed, divided by the total number of specimens
332	classified as ZIKV primary (based on a positive result in the ZIKV EDIII IgG ELISA and a
333	negative result in the DENV FRNT50) or DENV unexposed (based on negative results in both
334	the CDC DENV IgG ELISA and the FRNT50), multiplied by 100.
335	Confidence interval
336	The 95% confidence interval (CI) of the estimated sensitivity and specificity was calculated
337	using the formula: $P\pm 1.96\sqrt{P(1-P)}/N$, where P is the sensitivity or specificity, and N is the
338	number of specimens tested. If the sensitivity or specificity was 100% it was substituted with
339	99.9% for P in the equation.
340	
341	
342	
343	
344	
345	
346	
347	

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

348 **Results**

349 *Performance on early convalescent specimens*

350	Seven tests were first evaluated for their capacity to detect anti-DENV IgG and their potential to
351	minimize detection of cross-reactive ZIKV IgG in early convalescent specimens (n=44) (Table
352	1). All (7/7) tests had at least overall moderate (75%) to high (100%) sensitivity for anti-DENV
353	IgG (Figure 1). The detection of anti-DENV IgG from secondary DENV was universal for all
354	tests; but differences in test sensitivity were observed for primary DENV. Sensitivity for anti-
355	DENV IgG in primary DENV specimens was lower in RDTs in comparison with ELISA tests.
356	The RDTs detected over half of the primary DENV specimens. ELISA tests displayed high
357	sensitivity for anti-DENV IgG in primary specimens, except for the SCIMEDX Dengue IgG
358	serum microwell ELISA, which had a sensitivity comparable to RDTs. Despite the high
359	sensitivity observed in the Focus DENV IgG DxSelect and InBios DENV Detect IgG ELISAs,
360	they were excluded from further evaluation due to the high (50-57 %) reactivity observed in
361	primary ZIKV specimens. Cross-reactivity in the remaining tests was low (7-14%) and
362	warranted further evaluation. No test had false positives in specimens from unexposed
363	individuals.

364 *Performance to detect previous dengue infections with a small panel of 44 specimens*

365 The 44-sample panel of specimens from non-ill children was used to assess 7 commercial anti-

366 DENV IgG tests for their performance to detect previous dengue infections (PDI-SP, n=44);

which included 5 tests that passed the EC panel and 2 IgG tests from CTK Biotech that became

368 commercially available during the course of our evaluation (Table 1). The tests with the highest

369 performance (specificity and sensitivity, respectively) were the Euroimmun DENV-1-4 IgG

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

370	ELISA (86%, 86%), the Euroimmun DENV NS1 IgG ELISA (95%, 68%), the CTK Onsite
371	Dengue IgG Rapid Test R0065C (95%, 82%) and the CTK Onsite Dengue IgG Rapid Test
372	R0065C 1.0 (95%, 68%) (Figure 2). The sensitivity of Biocan Dengue IgG/IgM Antibody Test
373	(27%), CTK Biotech OnSite Dengue IgG/IgM Combo Rapid (0%), and SCIMEDX Dengue IgG
374	serum microwell ELISA (23%) was overall very low and not suitable for pre-vaccination
375	screening. The test with the highest ZIKV cross-reactivity was the Euroimmun anti-DENV Type
376	1-4 ELISA IgG ELISA, which uses VLP antigen and had 3/14 primary ZIKV specimens test
377	positive.

378 *Performance to detect previous dengue virus infection with a community survey of 400*

379 specimens

380 The full-scale evaluation was done with the two Euroimmun ELISAs and the two CTK OnSite Dengue IgG rapid tests. From the 750 children (age 9-16) in the COPA cohort, 400 specimens 381 were selected for the test evaluation and categorized by immune status using the DENV/ZIKV 382 FRNT and an in-house DENV IgG assay, with a total of 36 monotypic DENV infections, 77 383 multitypic DENV infections, 56 primary ZIKV infections, 80 multi-flavivirus infections, and 151 384 unexposed (Table 2 and supplementary table 1). The four tests evaluated displayed a sensitivity 385 near or above the ACIP recommendation (74.1%-91.2%); and high specificity (91.8%-98.6%); 386 387 but only both versions of the CTK OnSite Dengue IgG rapid test reached the ACIP 388 recommended target of \geq 98% specificity (Table 3). The CTK OnSite rapid tests displayed a similar low proportion (~1.8%) of false positives in the ZIKV primary and unexposed 389 specimens. Of those two tests, only the CTK OnSite Dengue IgG rapid test R0065C with 76.2% 390 391 sensitivity surpassed the \geq 75% performance recommended by the ACIP. The CTK OnSite 392 Dengue IgG Rapid Test R0065C-1.0 with equipment read yielded a sensitivity of 74.1% and

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

393	nearly achieved the desired performance standards. The visual reads of the CTK OnSite Dengue
394	IgG rapid test obtained by both laboratory technicians were identical for all specimens. Results
395	showed that although the higher sensitivity (89.6% for R0065C, 81.9% for R0065C-1.0) of the
396	rapid tests obtained when laboratory technicians performed the test read compared to the
397	equipment reads, came at the cost of reduced specificity (95.7% for R0065C, 96.6% for R0065C-
398	1.0) (Table 3). The ELISAs achieved 100% specificity in unexposed specimens but displayed
399	some cross-reactivity against ZIKV. Although the Euroimmun anti-DENV NS1 Type 1-4 ELISA
400	displayed a sensitivity (84.5%) high enough for pre-vaccination screening, it fell short on
401	specificity (97.1%). A higher specificity was observed in the Euroimmun ELISA using NS1 than
402	with the ELISA using VLPs as antigen that yielded a 91.8% specificity and sensitivity of 91.2%.
403	(Table 3). Differences in sensitivity between tests were more pronounced in the detection of
404	monotypic DENV specimens. Sensitivity for monotypic DENV was low to moderate (25.0-
405	72.2%) for most tests. Multitypic DENV specimens and those with DENV and ZIKV exposure
406	(multi-flavivirus) were detected with moderate to high sensitivity (≥83%) for all tests. The two
407	CTK OnSite Dengue IgG rapid test versions showed a reduction in sensitivity when read by the
408	manufacturer's equipment compared to the visual read (Table 3). Because the Alta reader may
409	not be available in all settings, we evaluated the performance of a combination of tests that could
410	be used without the reader. We found that combining the Euroimmun anti-DENV NS1 Type 1-4
411	ELISA and the CTK OnSite R0065C read visually by the laboratory technician in a two-test
412	algorithm, resulted in a specificity of 100% [98.2-100.0] and a sensitivity of 80.3% [74.0-85.7];
413	which meets the ACIP recommended performance criteria. Supplemental Figures 2-12 show
414	flow diagrams for all test combinations indicated in Table 3.

415

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

416 Additional evaluation of cross-reactivity

417	The current and future challenge of pre-vaccination screening arises largely because many
418	dengue endemic countries also experienced ZIKV transmission. Therefore, to ensure dengue test
419	specificity the Euroimmun anti-DENV NS1 Type 1-4 ELISA and CTK OnSite Dengue IgG rapid
420	tests were evaluated with an additional 63 specimens from unexposed healthy individuals from
421	Puerto Rico and well-characterized RT-PCR-confirmed past ZIKV infections from Nicaragua
422	(Table 4).
423	The highly specific Euroimmun anti-DENV NS1 Type 1-4 ELISA and CTK OnSite Dengue IgG
424	rapid tests were evaluated with 12 samples from primary ZIKV specimens with high ZIKV
425	neutralizing and binding antibody levels. The Euroimmun anti-DENV NS1 Type 1-4 ELISA IgG
426	ELISA yielded 4/12 positives and the CTK OnSite Dengue IgG Rapid Tests both had 1/12
427	positives (Table 5). Both numbers are higher than expected and suggest that high ZIKV antibody
428	levels could have an impact on test performance.
429	
430	
431	
432	
433	
434	
435	

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

437 **Discussion**

The FDA approval and subsequent ACIP recommendation of Sanofi Pasteur's Dengvaxia® has 438 439 created a need for a highly accurate test for pre-vaccination screening. In the current study, we 440 evaluated the performance of commercial anti-DENV IgG tests to determine which tests reached the ACIP's required performance characteristics. Our study used well-characterized DENV and 441 442 ZIKV specimens and included unexposed individuals from a dengue-endemic area, Puerto Rico, the United States territory with the largest number of dengue cases (4). The unbiased selection of 443 specimens from healthy individuals should approximate the expected test performance in the 444 community since most individuals experience asymptomatic DENV and ZIKV infections. As a 445 reference standard, we used a combination of the CDC DENV IgG assay and DENV FRNT50. 446 The correlation between the two assays was high with 399/400 specimens having concordant 447 results. Our results showed that only the CTK OnSite Dengue IgG rapid test R0065C read with 448 equipment reached the ACIP performance recommendation as a single test. Two tests were very 449 close to meeting the recommendations but missed either for sensitivity (CTK OnSite Dengue 450 IgG rapid test R0065C-1.0 with equipment read) or for specificity (Euroimmun anti-DENV NS1 451 Type 1-4 ELISA). Visual readings by the laboratory technicians resulted in increased CTK 452 453 OnSite Dengue IgG rapid test sensitivity, but decreased specificity. Therefore, test interpretation must be determined by reading with the manufacturer's equipment to ensure performance 454 standards are maintained. In settings in the United States where the reader is not available, 455 456 laboratory technicians could consider a visual read of the CTK OnSite Dengue IgG rapid test R0065C for pre-vaccination screening if a two-test algorithm is implemented with the 457 combination of the Euroimmun anti-DENV NS1 Type 1-4 ELISA. Importantly, the effectiveness 458 of screening is the same, regardless of whether the CTK OnSite Dengue IgG rapid test R0065C 459

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

460	or the Euroimmun anti-DENV NS1 Type 1-4 ELISA is performed first. The combined use of
461	these two tests resulted in the most sensitive and specific test algorithm that meets ACIP
462	recommendations. Our data shows that there are commercial tests available for use as a pre-
463	vaccination screening tool to confirm previous dengue infections and support safe vaccination
464	practices (21). The CDC Dengue Branch has serum specimen sets for additional test evaluations
465	and will provide updates of the results of these tests as they become available.
466	Our evaluation examined ZIKV cross-reactivity since it could interfere with pre-vaccination
467	screening. False-positives in the CTK OnSite Dengue IgG rapid test R0065C occurred at the
468	same frequency between ZIKV and non-ZIKV exposed individuals, but the Euroimmun anti-
469	DENV NS1 Type 1-4 ELISA yielded more false-positives for those exposed to ZIKV than for
470	those unexposed. We also performed limited testing with challenging ZIKV specimens that had
471	high antibody binding and neutralizations titers that suggest there is a possibility of an increase
472	in false positives in the event of ZIKV re-emergence.
473	Evaluations of commercial anti-DENV IgG tests have been limited by using convenient samples

of well-characterized acute specimens from different cohorts that may not represent real-world

475 scenarios (6). Moreover, a study evaluating commercial tests used for dengue diagnostics in

476 Puerto Rico suggest they would not meet ACIP recommendations (8). Another study, which

477 utilized data on virologically confirmed dengue infections collected before the Zika epidemic,

found that the sensitivities of rapid diagnostic tests (RDTs) (40-70%) were lower than those of

479 ELISAs (\geq 90%). However, consistent with our observations, ELISAs yielded a higher number of

480 false positives than RDTs in specimens with ZIKV or flavivirus exposure. (7). Another factor

that influences differences between the studies are the variance in the respective FRNT

482 comparator such as assay conditions, virus strains, and cut-off (FRNT50 vs. FRNT90). Only few

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

483	studies evaluated flavivirus cross-reactivity and did so separately from the specificity estimates.
484	Studies on samples from non-ill individuals show high sensitivity (>90%), but inadequate
485	specificity (<93.4%) for pre-vaccination screening. Most of the false positives were due to cross-
486	reactivity with other flaviviruses (10, 11).
487	Our study is not without limitations. Due to the low number of monotypic DENV specimens and
488	the low circulation of some DENV serotypes in Puerto Rico it was not possible for us to
489	determine sensitivity by serotype. It is also possible that some of our specimens are
490	misclassified. Our method of classifying specimens based on DENV IgG testing of acute (DPO
491	0-5) specimens was shown to correctly classify specimens approximately 85% of the time (22).
492	We could not definitively classify DENV specimens as primary and secondary DENV in healthy
493	individuals in the COPA cohort. Therefore, the impact of vaccination could be underestimated if
494	only monotypic DENV specimens were classified as primary DENV cases. Some of the
495	multitypic DENV specimens could indeed be primary DENV cases due to the cross-reactivity
496	between the DENV serotypes. The cross-reactivity could also cause the misclassification of a
497	small number of primary ZIKV specimens as multi-flavivirus and thereby result in a reduction of
498	test sensitivity. Lastly, we limited the number of tests evaluated to those with publicly available
499	information on test performance. It is possible that there are tests we did not evaluate that could
500	be used for pre-vaccination screening of previous dengue infection either alone or in
501	combination with another test.
502	In summary, the CTK OnSite Dengue IgG rapid test R0065C with equipment read was the only
503	test able to satisfy the ACIP recommendations for test performance to determine previous DENV

504 infection. However, the performance of this test in a two-test algorithm with the Euroimmun

anti-DENV NS1 Type 1-4 ELISA results in a performance that surpasses the minimum test

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

- 506 recommendations and reduces the concern of vaccinating individuals without previous dengue
- 507 infection while providing the benefits of vaccination, including decreased illness and
- 508 hospitalizations from dengue in the population at risk.

510 Table 1: Commercial anti-DENV IgG diagnostic tests evaluated.

Manufacturer	Product name	Test type	Catalog number	Package insert, date	Recommended specimen types	Period evaluated	Time to result	Required test volume
Biocan	Dengue IgG/IgM Antibody Test	Lateral flow	B803C	B803C, Rev 02/2016	S, P, & WB	EC, PDI- SP	15-20 min.	10 µL
CTK Biotech	Dengue IgG/IgM 3.0 Combo Rapid Test CE	Lateral flow	R0061C	PI-R0061C-RUO Rev. IP, 03/07/2019	S, P, & WB	PDI-SP, PDI-LP	20-25 min.	5 μL
CTK Biotech	CTK OnSite Dengue IgG Rapid Test	Lateral flow	R0065C	PI-R0065C-RUO Rev. B1.0, 10/20/2020	S, P, & WB	PDI-SP, PDI-LP	20-25 min.	5 µL
CTK Biotech	CTK OnSite Dengue IgG Rapid Test	Lateral flow	R0065C-1.0	PI-R0065C-A-RUO Rev. B1.1, 12/03/2021	S, P, & WB	PDI-SP, PDI-LP	20-25 min.	5 µL
Euroimmun	anti-DENV NS1 Type 1-4 ELISA IgG ELISA	ELISA	EI 266a-9601-1 G	EI_266a- 1G_A_UK_C02.doc, 02/28/2019	S, & P	EC, PDI- SP, PDI- LP	Minimum 2.5 hr	10 µL
Euroimmun	anti-DENV Type 1-4 ELISA IgG ELISA	ELISA	EI 266a-9601-2 G	EI_266a- 2G_A_UK_C01.doc, 08/05/2019	S, & P	EC, PDI- SP, PDI- LP	Minimum 2.5 hr	10 µL
Focus Diagnostics	Dengue Virus IgG DxSelect TM	ELISA	EL1500G	PI.EL1500G.OUS, Rev O 03/31/2011	S	EC	Minimum 2.5 hr	10 µL
InBios	DENV Detect TM IgG ELISA	ELISA	DDGS-R	9000089-04, 05/01/2018	S	EC	Minimum 2.5 hr	4 μL
SCIMEDX	Dengue IgG Serum Microwell ELISA	ELISA	DEN-G	DEN-G Rev F, 06/19/17	S	EC, PDI- SP	Minimum 0.5 hr	10 µL


511 Note: serum (S), plasma (P), whole blood (WB), early convalescence (EC, n=44), remote prior dengue infection small panel(PDI-SP, n=44), and

512 large panel (PDI-LP, n=400)

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

513 Figure 1. Comparison of anti-DENV IgG commercial tests evaluated for specificity and sensitivity with

514 specimens collected during early convalescence.



- 516 Note: Circles represent the number of specimens tested and are not in the same order by column.
- 517 Figure 2. Comparison of anti-DENV IgG commercial tests evaluated for specificity and sensitivity of
- 518 previous dengue infection in serum specimens collected from non-ill children (9-16 years of age).

Test	unexposed (8)	primary ZIKV (14)	monotypic DENV	(13)	multitypic DENV (9)	Specificity	Sensitivity
EUROIMMUN DENV 1-4 IgG ELISA	00000000	000000000000000000000000000000000000000	0000000000	000	000000000	86%	86%
EUROIMMUN DENV NS1 IgG ELISA	00000000	000000000000000000000000000000000000000	00000000000	000	00000000	95%	68%
SCIMEDX Dengue IgG serum microwell ELISA	00000000	000000000000000000000000000000000000000	0000000000	000	000000000	100%	23%
Biocan Dengue IgG/IgM Antibody Test	00000000	000000000000000000000000000000000000000	0000000000	000	00000000	100%	27%
CTK Biotech OnSite Dengue IgG/IgM Combo Rapid	00000000	000000000000000000000000000000000000000	0000000000	000	000000000	100%	0%
CTK OnSite Dengue IgG Rapid Test (R0065C)	00000000	00000000000000000	0000000000	000	00000000	95%	82%
CTK OnSite Dengue IgG Rapid Test (R0065C-1.0)	00000000	000000000000000000000000000000000000000	000000000000	000	000000000	95%	68%
N=44	Sp	ecificity Panel (22)	Sensit	tivity	Panel (22)		
	Dengue IgC	3 Interpretation					
	 negative/nc equivocal/b positive/rea 	orderline/weakly reactive					
519							

520 Note: Circles represent the number of specimens tested and are not in the same order by column.

521

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

523 Table 2: Immune status classification of 400 specimens used to evaluate use of DENV IgG tests to

524 determine PDI.

Immune Status	NIH FRNT50 DENV	ZIKV EDIII IgG ELISA	CDC DENV IgG	TOTAL = 400
Monotypic DENV	POSITIVE (one serotype)	NEGATIVE	POSITIVE	DENV-1= 16 DENV-2= 12 DENV-3= 4 <u>DENV-4= 4</u> ALL= 36
Multitypic DENV	POSITIVE (≥2 serotypes)	NEGATIVE	POSITIVE	77
Primary ZIKV	NEGATIVE	POSITIVE	ANY RESULT	56
Multi-flavivirus	POSITIVE (≥1 serotype)	POSITIVE	POSITIVE	80
Unexposed	NEGATIVE	NEGATIVE	NEGATIVE	150
Unexposed	POSITIVE	NEGATIVE	NEGATIVE	0
Unexposed	NEGATIVE	NEGATIVE	POSITIVE	1

525

526

528

529

530

531

532

- Table 3: Specificity and sensitivity of commercial anti-DENV IgG tests used to determine previous dengue infection in 400 healthy
- individuals with specimens classified by virus neutralization and CDC DENV IgG ELISA

% Specificity [95% CI]% Cross- reactivity [95% CI]% Sensitivity [95% Confidence Intel				-			
TEST	UNEXPOSED + ZIKV PRIMARY N=207	UNEXPOSED N=151	ZIKV PRIMARY N=56	ALL DENV N=193	MONOTYPIC DENV N=36	MULTITYPIC DENV N=77	MULTI- FLAVIVIRUS N=80
Euroimmun anti-DENV NS1 Type 1-4 ELISA IgG ELISA	97.1 [93.8-98.9]	100 [97.6-100.0]	10.7 [4.0-21.9]	84.5 [78.6-89.3]	55.6 [38.1-72.1]	92.2 [83.8-97.1]	90.0 [81.2-95.6]
Euroimmun anti-DENV Type 1-4 ELISA IgG ELISA	91.8 [87.2-95.1]	100 [97.6-100.0]	30.4 [18.8-44.1]	91.2 [86.3-94.8]	72.2 [54.8-85.8]	96.1 [89.0-99.2]	95.0 [87.7-98.6]
CTK OnSite Dengue IgG Rapid Test R0065C visual read	95.7 [91.9-98.0]	94.7 [89.8-97.7]	1.8 [0.0-9.6]	89.6 [84.5-93.6]	66.7 [49.0-81.4]	94.8 [87.2-98.6]	95.0 [87.7-98.6]
CTK OnSite Dengue IgG Rapid Test R0065C equipment read	98.1 [95.1-99.5]	98.0 [94.3-99.6]	1.8 [0.0-9.6]	76.2 [69.5-82.0]	38.9 [23.1-56.5]	83.1 [72.9-90.7]	86.3 [76.7-92.9]
CTK OnSite Dengue IgG Rapid Test R0065C-1.0 visual read	96.6 [93.2-98.6]	96.0 [91.6-98.5]	1.8 [0.0-9.6]	81.9 [75.7-87.0]	44.4 [27.9-61.9]	90.9 [82.2-96.3]	90.0 [81.2-95.6]
CTK OnSite Dengue IgG Rapid Test R0065C-1.0 equipment read	98.6 [95.8-99.7]	98.7 [95.3-99.8]	1.8 [0.0-9.6]	74.1 [67.3-80.1]	25.0 [12.1-42.2]	85.7 [75.9-92.7]	85.0 [75.3-92.0]
+ CTK OnSite Dengue IgG Rapid Test R0065C visual read	100 [98.2-100.0]	100 [97.6-100.0]	0.0 [0.0-6.4]	80.3 [74.0-85.7]	38.9 [23.1-56.5]	89.6 [80.6-95.4]	90.0 [81.2-95.6]
+ CTK OnSite Dengue IgG Rapid Test R0065C equipment read	100 [98.2-100.0]	100 [97.6-100.0]	0.0 [0.0-6.4]	75.7 [69.0-81.5]	33.3 [18.6-51.0]	84.4 [74.4-91.7]	86.3 [76.7-92.9]
+ CTK OnSite Dengue IgG Rapid Test R0065C-1.0 visual read	100 [98.2-100.0]	100 [97.6-100.0]	0.0 [0.0-6.4]	76.2 [69.5-82.0]	27.8 [14.2-45.2]	87.0 [77.4-93.6]	87.5 [78.2-93.8]
+ CTK OnSite Dengue IgG Rapid Test R0065C-1.0 equipment read	100 [98.2-100.0]	100 [97.6-100.0]	0.0 [0.0-6.4]	73.6 [66.8-79.7]	25.0 [12.1-42.2]	84.4 [74.4-91.7]	85.0 [75.3-92.0]
+ Euroimmun anti-DENV Type 1-4 ELISA IgG ELISA	98.1 [95.1-99.5]	100 [97.6-100.0]	7.1 [2.0-17.3]	82.9 [76.8-87.9]	50.0 [32.9-67.1]	90.9 [82.2-96.3]	90.0 [81.2-95.6]

Combined with Euroimmun anti-DENV NS1 Type 1-4 ELISA IgG ELISA

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

- 536 Table 4: Specificity of high performing commercial anti-DENV IgG tests used to determine PDI with
- 537 specimens from unexposed healthy individuals from Puerto Rico and past ZIKV infections from
- 538 Nicaragua.

%	% Cross- reactivity [95% CI]		
TEST	UNEXPOSED + ZIKV PRIMARY N=63	UNEXPOSED N=41	ZIKV PRIMARY N=22
Euroimmun anti-DENV			
NS1 Type 1-4 ELISA	96.8	100	9.1
IgG ELISA	[89.0-99.6]	[91.4-100.0]	[1.1-29.2]
Euroimmun anti-DENV			
Type 1-4 ELISA IgG	95.2	100	13.6
ELISA	[86.7-99.0]	[91.4-100.0]	[2.9-34.9]
CTK OnSite Dengue IgG Rapid Test R0065C visual read	98.4 [91.5-99.7]	100 [91.4-100.0]	4.6 [0.1-22.8]
CTK OnSite Dengue IgG Rapid Test R0065C-1.0 visual read	98.4 [91.5-99.7]	100 [91.4-100.0]	4.6 [0.1-22.8]

539

540

541

542

543

544

545

546

547

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

549 Table 5. Specimens with high ZIKV antibody tested in commercial anti-DENV IgG tests.

	Test	Cross-reactiv#50
	Euroimmun anti-DENV NS1 Type 1-4 ELISA IgG ELISA	4/12 (33%)
	CTK OnSite Dengue IgG Rapid Test R0065C	1/12 (8%)
	CTK OnSite Dengue IgG Rapid Test R0065C-1.0	1/12 (8%)
551		<u> </u>
552		
553		
554		
555		
556		
557		
558		
559		
560		
561		
562		
563		
564		
565		

Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS,

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

566 References

1.

567

568 Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-7. 569 2. Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, Pigott DM, Shearer FM, 570 571 Johnson K, Earl L, Marczak LB, Shirude S, Davis Weaver N, Gilbert M, Velayudhan R, Jones P, 572 Jaenisch T, Scott TW, Reiner RC, Hay SI. 2019. The current and future global distribution and 573 population at risk of dengue. Nature Microbiology 4:1508-1515. 574 3. Katzelnick LC, Zambrana JV, Elizondo D, Collado D, Garcia N, Arguello S, Mercado JC, Miranda T, 575 Ampie O, Mercado BL, Narvaez C, Gresh L, Binder RA, Ojeda S, Sanchez N, Plazaola M, Latta K, 576 Schiller A, Coloma J, Carrillo FB, Narvaez F, Halloran ME, Gordon A, Kuan G, Balmaseda A, Harris 577 E. 2021. Dengue and Zika virus infections in children elicit cross-reactive protective and 578 enhancing antibodies that persist long term. Sci Transl Med 13:eabg9478. 579 4. Paz-Bailey G, Adams L, Wong JM, Poehling KA, Chen WH, McNally V, Atmar RL, Waterman SH. 580 2021. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 70:1-16. 581 582 5. Fongwen N, Wilder-Smith A, Gubler DJ, Ooi EE, EM TS, de Lamballerie X, Olliaro PL, Peeling RW. 583 2021. Target product profile for a dengue pre-vaccination screening test. PLoS Negl Trop Dis 584 15:e0009557. Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW. 2019. Rapid diagnostic 585 6. 586 tests for determining dengue serostatus: a systematic review and key informant interviews. Clin 587 Microbiol Infect 25:659-666. 588 7. Bonaparte M, Zheng L, Garg S, Guy B, Lustig Y, Schwartz E, DiazGranados CA, Savarino S, 589 Ataman-Onal Y. 2019. Evaluation of rapid diagnostic tests and conventional enzyme-linked 590 immunosorbent assays to determine prior dengue infection. J Travel Med 26. 591 8. Bonaparte M, Huleatt J, Hodge S, Zheng L, Lustig Y, DiazGranados CA, Ataman-Onal Y, Savarino 592 S. 2020. Evaluation of dengue serological tests available in Puerto Rico for identification of prior 593 dengue infection for prevaccination screening. Diagn Microbiol Infect Dis 96:114918. 594 9. Echegaray F, Laing P, Hernandez S, Marguez S, Harris A, Laing I, Chambers A, McLennan N, 595 Sugiharto VA, Chen HW, Villagran SV, Collingwood A, Montoya M, Carrillo FB, Simons MP, 596 Cooper PJ, Lopez A, Trueba G, Eisenberg J, Wu SJ, Messer W, Harris E, Coloma J, Katzelnick LC. 597 2021. Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. Front 598 Immunol 12:703887. Lopez AL, Adams C, Ylade M, Jadi R, Daag JV, Molloy CT, Agrupis KA, Kim DR, Silva MW, Yoon IK, 599 10. 600 White L, Deen J, de Silva AM. 2021. Determining dengue virus serostatus by indirect IgG ELISA 601 compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective 602 population-based study. Lancet Glob Health 9:e44-e51. 603 11. Daag JV, Ylade M, Adams C, Jadi R, Crisostomo MV, Alpay R, Aportadera ETC, Yoon IK, White L, 604 Deen J, de Silva AM, Lopez AL. 2021. Evaluation of a new point-of-care test to determine prior 605 dengue infection for potential use in pre-vaccination screening. Clin Microbiol Infect 27:904-908. 606 Medina FA, Vila F, Premkumar L, Lorenzi O, Paz-Bailey G, Alvarado LI, Rivera-Amill V, de Silva A, 12. Waterman S, Muñoz-Jordán J. 2021. Capacity of a Multiplex IgM Antibody Capture ELISA to 607 608 Differentiate Zika and Dengue Virus Infections in Areas of Concurrent Endemic Transmission. 609 The American journal of tropical medicine and hygiene. 610 13. Tomashek KM, Lorenzi OD, Andujar-Perez DA, Torres-Velasquez BC, Hunsperger EA, Munoz-611 Jordan JL, Perez-Padilla J, Rivera A, Gonzalez-Zeno GE, Sharp TM, Galloway RL, Glass Elrod M,

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

612		Mathis DL, Oberste MS, Nix WA, Henderson E, McQuiston J, Singleton J, Kato C, Garcia Gubern C,
613		Santiago-Rivera W, Cruz-Correa J, Muns-Sosa R, Ortiz-Rivera JD, Jimenez G, Galarza IE, Horiuchi
614		K, Margolis HS, Alvarado LI. 2017. Clinical and epidemiologic characteristics of dengue and other
615		etiologic agents among patients with acute febrile illness, Puerto Rico, 2012-2015. PLoS Negl
616		Trop Dis 11:e0005859.
617	14.	Sanchez-Gonzalez L, Adams LE, Saavedra R, Little EM, Medina NA, Major CG, Bruck M, Miranda
618		J, Rosado-Santiago C, Ryff K, Ortiz M, Brown G, Barrera R, Perez-Guerra CL, Rivera-Amill V, Paz-
619		Bailey G. 2021. Assessment of community support for Wolbachia-mediated population
620		suppression as a control method for Aedes aegypti mosquitoes in a community cohort in Puerto
621		Rico. PLoS Negl Trop Dis 15:e0009966.
622	15.	Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O, Elizondo D, Miranda
623		T, Bustos Carillo F, Mercado JC, Latta K, Schiller A, Segovia-Chumbez B, Ojeda S, Sanchez N,
624		Plazaola M, Coloma J, Halloran ME, Premkumar L, Gordon A, Narvaez F, de Silva AM, Kuan G,
625		Balmaseda A, Harris E. 2020. Zika virus infection enhances future risk of severe dengue disease.
626		Science 369:1123-1128.
627	16.	Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E.
628	10.	2017. Antibody-dependent enhancement of severe dengue disease in humans. Science 358:929-
629		932.
630	17.	Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ,
631	17.	Elkins WR, Chanock RM, Murphy BR, Whitehead SS. 2001. Attenuation and immunogenicity in
632		humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-
633		untranslated region. Am J Trop Med Hyg 65:405-13.
634	18.	Miagostovich MP, Nogueira RM, dos Santos FB, Schatzmayr HG, Araujo ES, Vorndam V. 1999.
635	10.	
636		Evaluation of an IgG enzyme-linked immunosorbent assay for dengue diagnosis. J Clin Virol 14:183-9.
	10	
637	19.	Adams C, Jadi R, Segovia-Chumbez B, Daag J, Ylade M, Medina FA, Sharp TM, Munoz-Jordan JL,
638		Yoon IK, Deen J, Lopez AL, de Silva AM, Premkumar L. 2021. Novel Assay to Measure
639	20	Seroprevalence of Zika Virus in the Philippines. Emerg Infect Dis 27:3073-3081.
640	20.	Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie
641		D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, Group
642		S. 2015. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.
643	24	BMJ 351:h5527.
644	21.	Prevention CfDCa. 05/10/2022 2022. Laboratory Testing Requirements for Vaccination with
645		Dengvaxia Dengue Vaccine (For Healthcare Providers).
646		https://www.cdc.gov/dengue/vaccine/hcp/testing.html. Accessed 11/18/2022.
647	22.	Nguyen THT, Clapham HE, Phung KL, Nguyen TK, TT DI, Nguyen THQ, Tran VN, Whitehead S,
648		Simmons C, Wolbers M, Wills B. 2018. Methods to discriminate primary from secondary dengue
649		during acute symptomatic infection. BMC Infect Dis 18:375.
650		
651		
652		
652		
653		
654		
655		

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

656 Acknowledgements

- 657 We are grateful to Dr. Luisa I. Alvarado, the SEDSS and COPA staff and study participants for
- 658 their contribution to this study.

659

660 Financial Support

- Funding was provided by the Division of Vector Borne Infectious Diseases, Centers for Disease
- 662 Control and Prevention, the Intramural Research Program of the NIAID, NIH and by grant
- numbers U01CK000437 and U01CK000580 to Vanessa Rivera-Amill.

664

- 665 **Disclosures**
- 666 No competing financial interests exist.

667

668 Disclaimer

- 669 The findings and conclusions in this report are those of the authors and do not necessarily
- 670 represent the views of the Centers for Disease Control and Prevention.


671

- 672
- 673
- ____


674


Evaluation of Dengue virus IgG Tests for pre-vaccination screening

- Figure S1. Sera from healthy children (ages 9-15) (n=400) living in Puerto Rico were tested in a focus
- 677 reduction neutralization test and 50% virus neutralization titers (FRNT50) for DENV-1 (A), DENV-2 (B),
- 678 DENV-3 (C), DENV-4 (D) and ZIKV (E) were determined as described in materials and shown according to
- 679 immune status classification.




Evaluation of Dengue virus IgG Tests for pre-vaccination screening






Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S3. STARD flow diagram for CTK OnSite Dengue IgG Rapid Test R0065C visual read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S4. STARD flow diagram for CTK OnSite Dengue IgG Rapid Test R0065C equipment read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S5. STARD flow diagram for CTK OnSite Dengue IgG Rapid Test R0065C-1.0 visual read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S6. STARD flow diagram for CTK OnSite Dengue IgG Rapid Test R0065C-1.0 equipment read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S7. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C visual read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S8. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C equipment read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S9. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C-1.0 visual read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S10. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C-1.0 equipment read




Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S11. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C visual read



Evaluation of Dengue virus IgG Tests for pre-vaccination screening

Figure S12. STARD flow diagram for Euroimmun DENV NS1 Type 1-4 IgG ELISA + CTK OnSite Dengue IgG Rapid Test R0065C visual read



Evaluation of Dengue virus IgG Tests for pre-vaccination screening

699 STARD checklist

Section & Topic	No	Item	Reported on page
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy	1
		(such as sensitivity, specificity, predictive values, or AUC)	
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	3
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	4-6
	4	Study objectives and hypotheses	5-6
METHODS			
Study design	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	7
Participants	6	Eligibility criteria	7
	7	On what basis potentially eligible participants were identified	7
		(such as symptoms, results from previous tests, inclusion in registry)	
	8	Where and when potentially eligible participants were identified (setting, location, and dates)	7
	9	Whether participants formed a consecutive, random or convenience series	7
Test methods	10a	Index test, in sufficient detail to allow replication	13
	10b	Reference standard, in sufficient detail to allow replication	8-11
		Rationale for choosing the reference standard (if alternatives exist)	9
	 12a	Definition of and rationale for test positivity cut-offs or result categories	14 (established by
		of the index test, distinguishing pre-specified from exploratory	manufacturers)
	12b	Definition of and rationale for test positivity cut-offs or result categories	8
		of the reference standard, distinguishing pre-specified from exploratory	
	13a	Whether clinical information and reference standard results were available	14
		to the performers/readers of the index test	
	13b	Whether clinical information and index test results were available	8
		to the assessors of the reference standard	
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	15-16
	15	How indeterminate index test or reference standard results were handled	14
	16	How missing data on the index test and reference standard were handled	16
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	N/A
	18	Intended sample size and how it was determined	14
RESULTS			
Participants	19	Flow of participants, using a diagram	30-40
	20	Baseline demographic and clinical characteristics of participants	7
	21 a	Distribution of severity of disease in those with the target condition	26, Table 3
	21b	Distribution of alternative diagnoses in those without the target condition	26, Table 3
	22	Time interval and any clinical interventions between index test and reference	14

Evaluation of Dengue virus IgG Tests for pre-vaccination screening

		standard	
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	24, 26
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	26, Table 3
	25	Any adverse events from performing the index test or the reference standard	12
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	21
	27	Implications for practice, including the intended use and clinical role of the index test	22
OTHER INFORMATION			
	28	Registration number and name of registry	
	29	Where the full study protocol can be accessed	
	30	Sources of funding and other support; role of funders	31